Article Text

THU0133 Early Introduction of Biologic Treatment is an Important Predictor of Sustained Favorable Outcome Including Clinical Remission in Early Arthritis, but not of Sustained Favorable Outcome on Structure and Function Only: Results from the Espoir Cohort
  1. C. Gaujoux-Viala1,2,
  2. L. Gossec1,
  3. M. Dougados3,
  4. F. Guillemin4,5,
  5. B. Fautrel1
  1. 1Paris 6 – Pierre et Marie Curie University; Rheumatology, Pitié-Salpêtrière Hospital, GRC-UPMC 08 – EEMOIS, Paris
  2. 2Montpellier I University; Rheumatology, Caremeau Hospital, CHU Nîmes, Nîmes
  3. 3Paris 5 – Descartes University; Rheumatology B, Cochin Hospital, Paris
  4. 4Lorraine University, Paris Descartes University, EA 4360 Apemac
  5. 5INSERM, CIC-EC CIE6, Nancy, France


Background The relevant elements to evaluate health states in RA should include remission, good functional ability and structural stability (1). The concept of favorable outcome could then be defined by the association of these 3 elements. An alternative definition of favorable outcome includes only the last 2 criteria: function + structure.

Objectives To assess which variables at baseline are associated with sustained favorable outcome over 3 years in early arthritis (EA) in daily clinical practice.

Methods - Patients: from the French cohort of EA ESPOIR (at least 2 swollen joints for less than 6 months and suspicion of RA) fulfilling the new ACR-EULAR criteria for RA at baseline.

- Outcome: favorable outcome was defined by a criterion representing good functional ability (HAQ ≤0.5 and HAQ deterioration ≤0.25) and a criterion representing structural damage (absence of progression of the Sharp score over 1 year) with or without remission according to the new criteria of ACR / EULAR. Patients with sustained favorable outcome (according to the two definitions, ie using 2 and 3 criteria) over 3 years were analyzed.

- Analysis: Multinomial and ordinal logistic regression were used to determine which variables at baseline were independently associated with sustained favorable outcome. Sensitivity analyses on different definition of ‘sustained’ favorable outcome and on the timing of the treatment’s introduction were performed.

Results 643 patients were analyzed (mean age of patients 48±12 years; 78% were women; mean DAS28 5.4±1.2). In all, 97 patients presented sustained favorable outcome using 2 criteria (function+structure) at least at 2 time-points and 29, sustained favorable outcome using 3 criteria. (function+structure+remission). In the logistic regression models, only low HAQ and morning stiffness were always associated with sustained favorable outcome whatever the definition used (3 or 2 criteria). Being younger, living with a partner and biological treatment during the first 6 months were associated with sustained favorable outcome using the 3 criteria (including remission). Being male, low Sharp score and no synthetic DMARD during the first year were associated with sustained favorable outcome using the 2 criteria (function+structure) (Table). To note the introduction of biological treatment after 6 months was not associated with sustained favorable outcome.

Conclusions Early initiation of biological treatment is an important predictor of sustained favorable outcome (function+structure+remission) but not of sustained favorable outcome on structure and function only.


  1. Felson DT et al. Ann Rheum Dis 2011; 70(3):404-13

Disclosure of Interest C. Gaujoux-Viala Grant/research support from: Pfizer, Nordic Pharma, L. Gossec: None Declared, M. Dougados: None Declared, F. Guillemin: None Declared, B. Fautrel Grant/research support from: Roche, Pfizer, MSD, Nordic Pharma

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.